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Abstract (150 words, max 150) 
Background: Lomitapide reduces low-density lipoprotein-cholesterol (LDL-C) but also high-
density lipoprotein-cholesterol (HDL-C) levels. The latter may reduce the clinical efficacy of 
lomitapide. We investigated the effect of lomitapide on HDL-C levels and on cholesterol efflux 
capacity (CEC) of HDL in patients with homozygous familial hypercholesterolemia (HoFH).  
Methods and results: Four HoFH patients were treated with increasing dosages of lomitapide. 
Lomitapide decreased LDL-C (range -34 to -89%). Total HDL-C levels decreased (range -16 to  -
34%) with a shift to buoyant HDL. ABCA1-mediated CEC decreased in all patients (range -39 to 
-99%). The changes of total, ABCG1- and SR-BI-mediated CEC were less consistent. 
Conclusion: Lomitapide decreased LDL-C and HDL-C levels. Our report raises the hypothesis 
that the anti-atherogenic potential of HDL seems to be unaffected as total CEC did not seem to 
change consistently. Combined with the reduction of atherogenic lipoproteins, the net effect of 
lomitapide appears to be beneficial in HoFH patients. 
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Introduction 
Homozygous familial hypercholesterolemia (HoFH) is a rare disease caused by mutations in the 
LDLR gene 1, 2. Untreated patients with HoFH are characterized by extremely raised low density 
lipoprotein-cholesterol levels (LDL-C) often exceeding 13 mmol/L, rendering them susceptible to 
unparalleled premature atherosclerotic cardiovascular disease (CVD) and extensive aortic valve 
calcification and stenosis 3, 4. Without treatment the majority of patients with HoFH do not survive 
beyond their twenties. Early diagnosis and treatment of HoFH is therefore essential 4.  
A new treatment option for HoFH patients has become available with the microsomal triglyceride 
transfer protein (MTP) inhibitor, lomitapide, which resulted in 38% reduction of LDL-C levels in a 
phase III trial in 29 HoFH patients 5. However, high-density lipoprotein-cholesterol (HDL-C) levels 
were reduced by 12% 5-7. Although HDL-C levels show an inverse correlation with CVD risk, there 
is increasing evidence that HDL-mediated cholesterol efflux capacity (CEC) is a better predictor 
of CVD risk compared to HDL-C 8, 9. HDL removes cholesterol from the arterial wall by mediating 
cholesterol efflux via different pathways involving ABCA1, ABCG1, SR-BI, or aqueous diffusion 
of free cholesterol 8.  
In the present study, we determined the effect of lomitapide treatment on the capacity of HDL to 
promote cholesterol efflux from macrophages in four HoFH patients. 
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Methods 
Study participants 
Four patients with HoFH receiving lomitapide as additional therapy in a clinical setting were 
included in the present study. They were amongst the first patients to be treated in a named-
patients-program worldwide. The diagnosis HoFH was based on genetic analysis and clinical 
phenotype (LDL-C>13mmol/L) 4.  
Three patients were recruited from the Erasmus Medical Center in the Netherlands and one from 
Palermo University Hospital in Italy, and were treated according to the prescribed protocol 10. 
All patients provided written informed consent. This study was approved by the Medical Ethical 
Committees of the Erasmus Medical Center in the Netherlands and Palermo University in Italy. 
 
Blood analysis and measurements 
Venous blood was obtained after a 10-hour overnight fast, prior to treatment with lomitapide and 
every three or four weeks during the titration period. Plasma and serum obtained after 
centrifugation were stored at -80ºC. All samples from different timepoints were analyzed in one 
run. 
Lipoprotein profiles were generated with density-gradient ultracentrifugation using the method 
described by Proudfoot et.al 11. Lipoproteins were separated according to their densities into HDL3 
(1·125-1·21 g/ml), HDL2 (1·062-1·125 g/ml), LDL(1·019-1·063 g/ml), and IDL+VLDL (<1·019 
g/ml) 12. Cholesterol and triglycerides were measured by an enzymatic method  using Selectra E 
(DDS Diagnostic system, Istanbul, Turkey). Lipoprotein(a) [Lp(a)] plasma levels were measured 
using the Diasys immunoturbidimetric assay 13.  
ApoB and ApoA-I levels were measured by immunoturbidimetry on a c311 automatic analyzer 
(Roche Diagnostics). HDL subclasses were separated by non-denaturing two dimensional (2D) 
electrophoresis, as previously described 14. The content of preβ-HDL was calculated as 
percentage of total ApoA-I signal by densitometric analysis. 
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Cholesterol loading capacity  
Cholesterol loading capacity (CLC) was measured as previously described 15 and defined as 
macrophage cholesterol content after exposure of cells to serum and expressed as µg cholesterol 
/ mg protein. 
Cholesterol efflux capacity . 
Serum was depleted of apoB-containing lipoproteins in order to isolate the serum HDL fraction as 
previously described 16. ApoB-depleted serum CEC was determined in human monocytes-derived 
macrophages THP-1 cultured in the presence of 100 ng/ml PMA for 72 hours to allow 
differentiation into macrophages. The apoB-depleted serum CEC specific for the three cholesterol 
efflux pathways (ABCA1, ABCG1, SR-BI) was evaluated in established cell culture models, as 
previously described 17, 18. Cellular cholesterol content before and after serum exposure was 
measured fluorimetrically as previously described 15.  
 
Statistical analysis 
We performed descriptive analyses at baseline and during lomitapide treatment values and we 
present data as percentage change from baseline. The number of participants did not allow 
statistical inference. We used Microsoft Excel and Prism Graphpad 5 for the drawing of 
statistical graphs and data analysis.  
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Results 
Baseline characteristics 
The baseline characteristics of the 4 patients are shown in Table 1. Patients 1, 3, and 4 had a 
history of CVD.  All patients had some gastrointestinal-symptoms during lomitapide treatment but 
complaints were minimalized by a low-fat diet. Lomitapide treatment was interrupted in patient 1 
because of non-adherence and in patient 4 because of persistent liver enzymes elevations >5 
times upper limit of normal during treatment, which returned to normal after discontinuation of 
lomitapide.  
 
Atherogenic lipoproteins 
As expected the triglyceride levels (measured in intermediate density lipoprotein and very low 
density lipoprotein (IDL+VLDL)) decreased strongly in all 4 patients (range -78 to -30%). LDL-C 
and apoB levels decreased in a dose-dependent manner (range -34 to -89% and -42 to -89%, 
respectively). Patient 2 and 3 achieved the LDL-C treatment target levels on maximum tolerated 
lomitapide dose. Patient 3 was treated with LDL-apheresis once every 1-2 weeks. This frequency 
was reduced to once every 8 to 10 weeks during lomitapide treatment. Lp(a) decreased in patient 
1-3 (-20% to -74%), but remained unchanged in patient 4. 
The CLC of sera of the patients decreased by an average of 20% at maximum lomitapide dose 
in comparison to baseline (from 53.6 ± 18.0 to 42.8 ± 12.3 ug cholesterol/mg cell protein). 
 
HDL, ApoA-I and cholesterol efflux capacity 
Figure 1A shows the individual cholesterol levels in total HDL-C and in HDL subclasses with 
increasing dosages of lomitapide of the 4 patients individually. The change in HDL-C levels (range 
-11 to -34%) was observed during treatment with lomitapide 5 mg/day. In all patients, HDL-C 
levels remained stable with increasing lomitapide dosage. The reduction in HDL-C levels varied 
per HDL subclass, the HDL3/HDL2 ratio remained stable in patient 1 and decreased in the others 
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(range -16 to -68%). Apo-AI levels and the content of Preβ-HDL decreased with lomitapide 
treatment (range -9 to -47% and -6 to -40%, respectively). This decrease was most pronounced 
with 5 mg/day lomitapide treatment.  
Figures 1B, 1C, 1D and 1E show the effect of lomitapide treatment on total CEC, and on 
cholesterol efflux via the different pathways for the four patients individually. Changes in total, SR-
BI-mediated and ABCG1-mediated cholesterol efflux were inconsistent. ABCA1-mediated 
cholesterol efflux decreased (-39 to -99%) in all patients. 
  
Table 1. Baseline characteristics. 
* LDL-apheresis once every 1-2 weeks
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Figure 1. HDL levels and total HDL-mediated CEC and CEC pathways at baseline and 
during lomitapide treatment per individual 
A. HDL-C levels (HDL3+HDL2) B. Total cholesterol efflux capacity (CEC) of apoB-depleted 
serum with increasing lomitapide daily dose. C. HDL-mediated cholesterol efflux via ABCA1.  
D. HDL-mediated cholesterol efflux via SR-BI. E. HDL-mediated cholesterol efflux via ABCG1. 
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Discussion 
Our data confirm that lomitapide treatment decreases HDL-C levels. In depth analysis show a 
shift in HDL subclasses to larger buoyant HDL2. ABCA1-mediated cholesterol efflux decreased 
in all four HoFH patients, whereas changes in efflux via ABCG1, SR-BI and total cholesterol 
efflux were less consistent. 
Previous studies showed that lomitapide treatment is associated with a moderate decrease of 
both HDL-C and ApoA-I levels during the titration period of the drug 5-7. In line, we found a 
decrease in the levels of HDL-C, ApoA-I, preβ-HDL, and HDL3-C, which was most prominent 
on the lowest dose of lomitapide and remained stable thereafter. However, a shift of HDL to 
larger and more buoyant particles was observed with HDL2-C levels remaining unchanged or 
increased. A reduced formation of HDL during lipolysis of predominantly postprandial 
triglyceride rich lipoproteins (TGRL) may underlie the reduction in HDL and ApoA-I levels and 
the alterations in HDL subclass levels. Additionally, lomitapide may reduce the levels of HDL 
derived from the intestine, since MTP-deficiency has been reported to reduce HDL-cholesterol 
secretion from the intestine in mice 19-21. In line with this shift in HDL subclasses, the ABCA1-
mediated cholesterol efflux was decreased in all patients, whereas changes in the ABCG1- 
and SR-BI-mediated cholesterol efflux were less consistent. 
As expected, lomitapide treatment  decreased LDL-C and apoB levels substantially as well as 
the other atherogenic lipoproteins, i.e. IDL, VLDL, and Lp(a) 5. Consistently, we found that 
lomitapide reduced the macrophage CLC of serum of all patients. This reflects the improved 
anti-atherosclerotic potential despite the moderate decrease of HDL-C 22.  
 
Limitations 
The major limitation of this study is the small number of participants. Although two of the 
patients stopped lomitapide treatment this did not interfere with our analyses. 
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Conclusions 
Lomitapide treatment substantially lowered LDL-C levels, though it moderately reduced HDL-
C levels. However, HDL seemed to shift from HDL3 to the larger and more buoyant HDL2. In 
addition, the ABCA1-mediated cholesterol efflux decreased, whereas other pathways did not 
change consistently. Our report raises the hypothesis that the anti-atherogenic potential of 
HDL seems to be unaffected as total CEC did not seem to change consistently despite 
decreased HDL-C levels. Combined with the reduction of atherogenic lipoproteins, the net 
effect of lomitapide appears to be beneficial in HoFH patients. 
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